Trials / Completed
CompletedNCT01677455
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Synta Pharmaceuticals Corp. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.
Conditions
- Breast Cancer
- HER-2 Positive Breast Cancer
- Triple Negative Breast Cancer
- ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ganetespib | Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle. |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2015-04-01
- Completion
- 2015-08-01
- First posted
- 2012-09-03
- Last updated
- 2015-11-05
Locations
25 sites across 8 countries: United States, Argentina, Belgium, Brazil, Peru, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01677455. Inclusion in this directory is not an endorsement.